Susquehanna Portfolio Strategies’s Vanda Pharmaceuticals VNDA Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.81M	Buy	262,110 +111,683	+74%	+$861K	0.03%	512
2025 Q4	$1.33M	Buy	150,427 +39,087	+35%	+$215K	0.02%	588
2025 Q3	$556K	Buy	111,340 +14,281	+15%	+$66.1K	0.01%	811
2025 Q2	$458K	Buy	+97,059	New	+$424K	0.01%	673
2024 Q4	–	Sell	-52,547	Closed	-$246K	–	321
2024 Q3	$246K	Hold	52,547	–	–	0.02%	299
2024 Q2	$297K	Hold	52,547	–	–	0.01%	424
2024 Q1	$216K	Sell	52,547 -99,902	-66%	-$400K	0.01%	725
2023 Q4	$643K	Buy	+152,449	New	+$615K	0.01%	707

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna Portfolio Strategies's VNDA Position: Q1 2026 in Review

Susquehanna Portfolio Strategies increased its Vanda Pharmaceuticals (VNDA) stake by 74% in Q1 2026, buying an estimated $861K and bringing the position to 262,110 shares worth $1.81M. The position accounts for 0.03% of the portfolio, ranked #512.

Susquehanna Portfolio Strategies first reported a position in VNDA in Q4 2023 and has held it in 8 quarters since. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

Susquehanna Portfolio Strategies held 262,110 shares of Vanda Pharmaceuticals worth $1.81M as of Q1 2026.
Susquehanna Portfolio Strategies bought 111,683 Vanda Pharmaceuticals shares in Q1 2026, an estimated $861K.
Vanda Pharmaceuticals made up 0.03% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #512 holding.
Susquehanna Portfolio Strategies first reported a position in Vanda Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.